PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

Type of Cancer
Blood Disorders Various

Site
Sparta

Sponsor
Incyte

Protocol Number
INCB-MA-PV-401

Cancer Diagnosis
Polycythemia vera

Protocol Title
PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC AND COMMUNITY CLINICAL PRACTICES (REVEAL)

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204